Biomet, Inc. has reached a settlement amounting to $56 million in Multi-District Litigation (MDL) 2391 relating to its M2A Magnum Hip Implant Products.
The metal-on-metal joint replacement/resurfacing story rumbles on, the original goal of providing prostheses with greater durability being replaced with myriad claims of undue pain, need for revision surgery and even hints at cancer formation, although there is no evidence for the latter. What’s backed up by data is the high risk of failure from many of these devices, the finger being pointed at accumulation of so-called wear particles in and around the joint.
The U.S. Food and Drug Administration (FDA) reports that in 2011, metal-on-metal devices were linked to more than 12,000 adverse medical events, compared with 6,332 for other types of implants.
The Liability Litigation related to claims associated with Biomet’s metal-on-metal hip products pending in the United States District Court for the Northern District of Indiana, South Bend Division.
Courts across the country saw hundreds of plaintiffs claiming that the hip device led to injuries, although Biomet maintains that the injuries, losses and damages were not due to its hip implants.
The lawsuits were combined and jointly heard at the federal court of Indiana, with the agreement extending to all pending cases, and any future lawsuit filed in a federal court on or before April 15, 2014.
Plaintiffs who have received a Biomet M2a 38 or M2a Magnum hip replacement system as part of an initial hip replacement that was rectified more than 180 days after it was implanted shall receive a base award of $200,000.
Source: Biomet, Inc., Reuters